Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells

BMC Molecular Biology

Volumn 11, Issue , 2010, Pages

  Bélanger, Anne Sophie ^a   Tojcic, Jelena ^a   Harvey, Mario ^a   Guillemette, Chantal ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARRIER PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; DNA; DNA METHYLTRANSFERASE INHIBITOR; GLUCURONOSYLTRANSFERASE 1A1; HEPATOCYTE NUCLEAR FACTOR 1; LUCIFERASE; NUCLEAR FACTOR Y; OCTAMER TRANSCRIPTION FACTOR 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDX2; UPSTREAM STIMULATORY FACTOR 1; UPSTREAM STIMULATORY FACTOR 2; 5 AZA 2' DEOXYCYTIDINE 5' TRIPHOSPHATE; 5-AZA-2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE; AZACITIDINE; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CYTIDINE TRIPHOSPHATE; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE;

ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DNA METHYLATION; DRUG GLUCURONIDATION; DRUG INACTIVATION; DRUG METABOLISM; ENZYME ASSAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN INTERACTION; CELL STRAIN HCT116; CELL STRAIN HT29; COLON TUMOR; CPG ISLAND; GEL MOBILITY SHIFT ASSAY; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; UPREGULATION;

AZACITIDINE; BASE SEQUENCE; COLONIC NEOPLASMS; CPG ISLANDS; CYTIDINE TRIPHOSPHATE; DNA METHYLATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HCT116 CELLS; HEPATOCYTE NUCLEAR FACTOR 1; HT29 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; UP-REGULATION;

EID: 77649322609     PISSN: None     EISSN: 14712199     Source Type: Journal    
DOI: 10.1186/1471-2199-11-9     Document Type: Article

References (51)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343(13):905-914. 10.1056/NEJM200009283431302, 11006366.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355(9209):1041-1047. 10.1016/S0140-6736(00)02034-1, 10744089.
3. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352(9138):1407-1412. 10.1016/S0140-6736(98)03085-2, 9807986.
4. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991, 51(16):4187-4191.
5. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998, 58(3):468-472.
6. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002, 62(3):608-617. 10.1124/mol.62.3.608, 12181437.
7. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo A, Ratain MJ. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999, 65(5):576-582. 10.1016/S0009-9236(99)70078-0, 10340924.
8. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, Sawada J. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001, 31(10):687-699. 10.1080/00498250110057341, 11695848.
9. Cummings J, Boyd G, Ethell BT, Macpherson JS, Burchell B, Smyth JF, Jodrell DI. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol 2002, 63(4):607-613. 10.1016/S0006-2952(01)00812-7, 11992628.
10. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004, 4(12):988-993. 10.1038/nrc1507, 15573120.
11. Laird PW. Cancer epigenetics. Hum Mol Genet 2005, 14(Spec No 1):R65-76. 10.1093/hmg/ddi113, 15809275.
12. Al-Romaih K, Somers GR, Bayani J, Hughes S, Prasad M, Cutz JC, Xue H, Zielenska M, Wang Y, Squire JA. Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation. Cancer Cell Int 2007, 7(14). 2034371, 17845729.
13. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999, 96(15):8681-8686. 10.1073/pnas.96.15.8681, 17576, 10411935.
14. Gagnon JF, Bernard O, Villeneuve L, Tetu B, Guillemette C. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 2006, 12(6):1850-1858. 10.1158/1078-0432.CCR-05-2130, 16551870.
15. Clark SJ, Harrison J, Molloy PL. Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 1997, 195(1):67-71. 10.1016/S0378-1119(97)00164-9, 9300822.
16. Gaston K, Fried M. CpG methylation has differential effects on the binding of YY1 and ETS proteins to the bi-directional promoter of the Surf-1 and Surf-2 genes. Nucleic Acids Res 1995, 23(6):901-909. 10.1093/nar/23.6.901, 306783, 7731802.
17. Umezawa A, Yamamoto H, Rhodes K, Klemsz MJ, Maki RA, Oshima RG. Methylation of an ETS site in the intron enhancer of the keratin 18 gene participates in tissue-specific repression. Mol Cell Biol 1997, 17(9):4885-4894. 232341, 9271368.
18. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002, 21(35):5496-5503. 10.1038/sj.onc.1205602, 12154410.
19. Gardner-Stephen DA, Gregory PA, Mackenzie PI. Identification and characterization of functional hepatocyte nuclear factor 1-binding sites in UDP-glucuronosyltransferase genes. Methods Enzymol 2005, 400:22-46. 10.1016/S0076-6879(05)00002-9, 16399341.
20. Gardner-Stephen DA, Mackenzie PI. Isolation of the UDP-glucuronosyltransferase 1A3 and 1A4 proximal promoters and characterization of their dependence on the transcription factor hepatocyte nuclear factor 1alpha. Drug Metab Dispos 2007, 35(1):116-120. 10.1124/dmd.106.012203, 17050649.
21. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. Coordinate regulation of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 genes by hepatocyte nuclear factor 1alpha and the caudal-related homeodomain protein 2. Mol Pharmacol 2004, 65(4):953-963. 10.1124/mol.65.4.953, 15044625.
22. Gardner-Stephen DA, Mackenzie PI. Hepatocyte nuclear factor1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4alpha. Pharmacogenet Genomics 2007, 17(1):25-36.
23. Gardner-Stephen DA, Mackenzie PI. Liver-enriched transcription factors and their role in regulating UDP glucuronosyltransferase gene expression. Curr Drug Metab 2008, 9(5):439-452. 10.2174/138920008784746409, 18537579.
24. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 2004, 199(3):354-363. 10.1016/j.taap.2004.01.008, 15364550.
25. Mackenzie PI, Gregory PA, Gardner-Stephen DA, Lewinsky RH, Jorgensen BR, Nishiyama T, Xie W, Radominska-Pandya A. Regulation of UDP glucuronosyltransferase genes. Curr Drug Metab 2003, 4(3):249-257. 10.2174/1389200033489442, 12769669.
26. Bernard P, Goudonnet H, Artur Y, Desvergne B, Wahli W. Activation of the mouse TATA-less and human TATA-containing UDP-glucuronosyltransferase 1A1 promoters by hepatocyte nuclear factor 1. Mol Pharmacol 1999, 56(3):526-536.
27. Cereghini S. Liver-enriched transcription factors and hepatocyte differentiation. Faseb J 1996, 10(2):267-282.
28. Gregory PA, Hansen AJ, Mackenzie PI. Tissue specific differences in the regulation of the UDP glucuronosyltransferase 2B17 gene promoter. Pharmacogenetics 2000, 10(9):809-820. 10.1097/00008571-200012000-00006, 11191885.
29. Ishii Y, Hansen AJ, Mackenzie PI. Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol Pharmacol 2000, 57(5):940-947.
30. Metz RP, Auyeung DJ, Kessler FK, Ritter JK. Involvement of hepatocyte nuclear factor 1 in the regulation of the UDP-glucuronosyltransferase 1A7 (UGT1A7) gene in rat hepatocytes. Mol Pharmacol 2000, 58(2):319-327.
31. Sawadogo M, Roeder RG. Interaction of a gene-specific transcription factor with the adenovirus major late promoter upstream of the TATA box region. Cell 1985, 43(1):165-175. 10.1016/0092-8674(85)90021-2, 4075392.
32. Chodosh LA, Carthew RW, Sharp PA. A single polypeptide possesses the binding and transcription activities of the adenovirus major late transcription factor. Mol Cell Biol 1986, 6(12):4723-4733. 367258, 3796614.
33. Sawadogo M, Van Dyke MW, Gregor PD, Roeder RG. Multiple forms of the human gene-specific transcription factor USF. I. Complete purification and identification of USF from HeLa cell nuclei. J Biol Chem 1988, 263(24):11985-11993.
34. Sawadogo M. Multiple forms of the human gene-specific transcription factor USF. II. DNA binding properties and transcriptional activity of the purified HeLa USF. J Biol Chem 1988, 263(24):11994-12001.
35. Kingsley-Kallesen ML, Kelly D, Rizzino A. Transcriptional regulation of the transforming growth factor-beta2 promoter by cAMP-responsive element-binding protein (CREB) and activating transcription factor-1 (ATF-1) is modulated by protein kinases and the coactivators p300 and CREB-binding protein. J Biol Chem 1999, 274(48):34020-34028. 10.1074/jbc.274.48.34020, 10567368.
36. Szentirmay MN, Yang HX, Pawar SA, Vinson C, Sawadogo M. The IGF2 receptor is a USF2-specific target in nontumorigenic mammary epithelial cells but not in breast cancer cells. J Biol Chem 2003, 278(39):37231-37240. 10.1074/jbc.M305791200, 12857727.
37. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 2007, 128(4):635-638. 10.1016/j.cell.2007.02.006, 17320500.
38. Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 1991, 251(4990):186-189. 10.1126/science.1987636, 1987636.
39. Watt F, Molloy PL. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev 1988, 2(9):1136-1143. 10.1101/gad.2.9.1136, 3192075.
40. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003, 63(11):2898-2904.
41. Paulson KE, Darnell JE, Rushmore T, Pickett CB. Analysis of the upstream elements of the xenobiotic compound-inducible and positionally regulated glutathione S-transferase Ya gene. Mol Cell Biol 1990, 10(5):1841-1852. 360529, 2325638.
42. Song CS, Jung MH, Kim SC, Hassan T, Roy AK, Chatterjee B. Tissue-specific and androgen-repressible regulation of the rat dehydroepiandrosterone sulfotransferase gene promoter. J Biol Chem 1998, 273(34):21856-21866. 10.1074/jbc.273.34.21856, 9705324.
43. Narvaez MJ, Anderson GR, Pickwell GV, Quattrochi LC. Characterization of adjacent E-box and nuclear factor 1-like DNA binding sequence in the human CYP1A2 promoter. J Biochem Mol Toxicol 2005, 19(2):78-86. 10.1002/jbt.20063, 15849719.
44. Edenberg HJ, Brown CJ. Regulation of human alcohol dehydrogenase genes. Pharmacogenetics 1992, 2(5):185-196. 10.1097/00008571-199210000-00001, 1339084.
45. Vaulont S, Puzenat N, Levrat F, Cognet M, Kahn A, Raymondjean M. Proteins binding to the liver-specific pyruvate kinase gene promoter. A unique combination of known factors. J Mol Biol 1989, 209(2):205-219. 10.1016/0022-2836(89)90273-8, 2585483.
46. Strassburg CP, Nguyen N, Manns MP, Tukey RH. Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 1998, 54(4):647-654.
47. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002, 21(26):4120-4128. 10.1038/sj.onc.1205518, 12037668.
48. Yu J, Shannon WD, Watson MA, McLeod HL. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005, 11(5):2053-2062. 10.1158/1078-0432.CCR-04-1254, 15756032.
49. Kirschbaum BJ, Pognonec P, Roeder RG. Definition of the transcriptional activation domain of recombinant 43-kilodalton USF. Mol Cell Biol 1992, 12(11):5094-5101. 360443, 1406684.
50. Houde M, Laprise P, Jean D, Blais M, Asselin C, Rivard N. Intestinal epithelial cell differentiation involves activation of p38 mitogen-activated protein kinase that regulates the homeobox transcription factor CDX2. J Biol Chem 2001, 276(24):21885-21894. 10.1074/jbc.M100236200, 11283019.
51. Jain S, Li Y, Patil S, Kumar A. HNF-1alpha plays an important role in IL-6-induced expression of the human angiotensinogen gene. Am J Physiol Cell Physiol 2007, 293(1):C401-410. 10.1152/ajpcell.00433.2006, 17475670.